Clinical Study on Cinobufagin Capsules Combined with Neoadjuvant Chemotherapy Regimen in the Treatment of HER2 Positive Breast Cancer
Objective:To explore the clinical efficacy of Cinobufagin Capsules combined with neoadjuvant chemotherapy regimen in the treatment of HER2 positive breast cancer.Method:A total of 86 patients with HER2 positive breast cancer admitted to Nanchang People's Hospital from February 2022 to February 2023 were included and divided into observation group and control group according to the random number table method,with 43 cases in each group.The control group was given neoadjuvant chemotherapy regimen of Trastuzumab + Pertuzumab + Taxanes combined with Platinum,and the observation group was additionally treated with Cinobufagin Capsules on the basis of neoadjuvant chemotherapy regimen.Clinical efficacy,tumor regression grading,serum related indicators[serum carcinoembryonic antigen(CEA),carbohydrate antigen 153(CA153),tissue polypeptide specific antigens(TPS),immunoglobulin(Ig)A,IgM and T lymphocyte subsets(CD3+,CD4+,CD8+)],quality of life[functional assessment of cancer therapy-breast(FACT-B)]and adverse reactions were compared between two groups.Result:There were no statistically significant differences in the objective response rate(51.16%vs 41.86%)and disease control rate(81.40%vs 74.42%)between the two groups(P>0.05).The tumor regression grading was not statistically different between the two groups(P>0.05).After treatment,the levels of CEA,CA153 and TPS in both groups were lower than those before treatment,and those in observation group were lower than those in control group(P<0.05).The levels of IgA,IgM,CD3+ and CD4+ in observation group after treatment were higher than those in control group(P<0.05).There was no statistical significance in CD8+ level between the two groups before and after treatment(P>0.05).After treatment,the scores of physiological status,emotional status,social/family status and additional attention in the observation group were higher than those of the control group(P<0.05).The incidence rates of headache and dizziness,digestive tract discomfort,cardiotoxicity,liver-kidney injury and myelosuppression in observation group were lower than those in control group(P<0.05).Conclusion:Cinobufagin Capsules combined with neoadjuvant chemotherapy regimen in the treatment of HER2 positive breast cancer can inhibit the tumor progression to a certain extent,improve the immune imbalance and quality of life,and reduce the toxic and side effects of chemotherapy.
Cinobufagin CapsulesNeoadjuvant chemotherapyHER2 positive breast cancerQuality of lifeTumor regression
国家科技期刊平台
NSTL
万方数据
